Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-17
DOI
10.1038/s41598-020-59671-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma
- (2018) Sarah S. Bernards et al. GYNECOLOGIC ONCOLOGY
- Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma
- (2018) Angel Chao et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
- (2018) Euan A. Stronach et al. MOLECULAR CANCER RESEARCH
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
- (2018) Xinxin Zhu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
- (2018) Jai N. Patel et al. BRITISH JOURNAL OF CANCER
- Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
- (2018) S. Y. Cindy Yang et al. Genome Medicine
- Genetic Versus Epigenetic BRCA1 Silencing Pathways
- (2017) Tingting Sun et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
- (2017) Katharina Prieske et al. Oncotarget
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
- (2015) Sean Kehoe et al. LANCET
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
- (2014) I. Ruscito et al. EUROPEAN JOURNAL OF CANCER
- BRCA1 promoter methylation is a marker of better response to platinum–taxane-based therapy in sporadic epithelial ovarian cancer
- (2014) T. Ignatov et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases
- (2014) XUEFENG BAI et al. Oncology Letters
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
- (2013) J. George et al. CLINICAL CANCER RESEARCH
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
- (2012) Jessica N McAlpine et al. MODERN PATHOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allele-specific copy number analysis of tumors
- (2010) P. Van Loo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
- (2009) David S. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More